相似文献
1
Targeting bone metastases starting from the preneoplastic niche: home sweet home.
Breast Cancer Res. 2011 Aug 16;13(4):111. doi: 10.1186/bcr2911.
2
The role of bone microenvironment, vitamin D and calcium.
Recent Results Cancer Res. 2012;192:33-64. doi: 10.1007/978-3-642-21892-7_2.
3
Fatal attraction: why breast cancer cells home to bone.
Breast Cancer Res. 2008;10(1):101. doi: 10.1186/bcr1848. Epub 2008 Jan 25.
4
Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
J Bone Miner Res. 2014 Sep;29(9):1938-49. doi: 10.1002/jbmr.2231.
5
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. doi: 10.1186/s13046-018-1001-2.
6
Targeting RANKL in breast cancer: bone metastasis and beyond.
Expert Rev Anticancer Ther. 2013 Feb;13(2):195-201. doi: 10.1586/era.12.177.
7
Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Clin Cancer Res. 2012 Jan 15;18(2):326-35. doi: 10.1158/1078-0432.CCR-10-2507. Epub 2011 Oct 26.
8
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Bone. 2007 Apr;40(4):981-90. doi: 10.1016/j.bone.2006.11.006. Epub 2006 Dec 28.
9
Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Med Hypotheses. 2013 Nov;81(5):805-6. doi: 10.1016/j.mehy.2013.08.032. Epub 2013 Sep 3.
10
Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Histol Histopathol. 2009 Feb;24(2):235-42. doi: 10.14670/HH-24.235.
引用本文的文献
1
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Oncotarget. 2016 May 17;7(20):29321-32. doi: 10.18632/oncotarget.8722.
2
A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.
J Bone Oncol. 2012 Jun 19;1(2):47-56. doi: 10.1016/j.jbo.2012.05.001. eCollection 2012 Sep.
本文引用的文献
1
Therapeutic targets for bone metastases in breast cancer.
Breast Cancer Res. 2011 Apr 6;13(2):207. doi: 10.1186/bcr2835.
2
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
PLoS One. 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234.
3
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
J Cell Physiol. 2011 Mar;226(3):780-4. doi: 10.1002/jcp.22402.
4
Ihh/Gli2 signaling promotes osteoblast differentiation by regulating Runx2 expression and function.
Mol Biol Cell. 2007 Jul;18(7):2411-8. doi: 10.1091/mbc.e06-08-0743. Epub 2007 Apr 18.
5
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
Nature. 2005 Dec 8;438(7069):820-7. doi: 10.1038/nature04186.
6
Applying the principles of stem-cell biology to cancer.
Nat Rev Cancer. 2003 Dec;3(12):895-902. doi: 10.1038/nrc1232.
7
DNA microarrays in breast cancer: the promise of personalised medicine.
Lancet. 2003 May 10;361(9369):1576-7. doi: 10.1016/S0140-6736(03)13322-3.
8
Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. doi: 10.1073/pnas.0530291100. Epub 2003 Mar 10.
9
In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set.
Physiol Genomics. 2002 Jul 12;10(1):13-20. doi: 10.1152/physiolgenomics.00035.2002.
Zotero 插件